Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on: October 24,2023

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on:October 24,2023

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on: December 19,2023

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on:December 19,2023

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on: December 21,2023

Survivors of childhood cancer have infection complications years after diagnosis

by Gina Bazer,Northwestern UniversityCredit: Pixabay/CC0 Public DomainInfectious complications continue to affect survivors of childhood cancer many years after initial diagnosis, according to f

Updated on:December 21,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on: December 25,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on:December 25,2023

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on: December 22,2023

Carbon oxide gas boosts photothermal therapy under mild temperature

by ZHANG Nannan,Chinese Academy of SciencesSchematic illustration of (A) synthesis route of mPEG(CO) and (B) the nanobomb consist of mPEG(CO) and PBPTV. (C) Schematic illustration of low-tempera

Updated on:December 22,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on: December 21,2023

Marker for therapy response in acute myeloid leukemia identified

byGerman Cancer Research CenterCell line sensitivity and additional patient data. A IC50s for VEN of 19 AML cell lines classified as primitive (Prim-AML, n = 11) or monocytic (Mono-AML, n = 8) t

Updated on:December 21,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on: December 19,2023

Patients prefer stool test to colonoscopy

byCedars-Sinai Medical CenterGraphical abstract. Credit:Clinical Gastroenterology and Hepatology(2022). DOI: 10.1016/j.cgh.2022.07.012Three-quarters of people prefer to do a fecal im

Updated on:December 19,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on: October 14,2023

Research reveals how synthesized plankton molecules inhibit cancer proteins

by Justin Jackson , Medical Xpressa, Chemical structure of reported PA and PB (in beige), and the revised structure of PB (in blue) in this work. b, A retrosynthesis targeting a minimally oxidized int

Updated on:October 14,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on: December 22,2023

Leukemia vulnerability discovered causing drug sensitivity

byJosep Carreras Leukaemia Research InstituteCells from acute lymphoblastic leukemia, a disease against which treatment with glutathione inhibitors has demonstrated preclinical efficacy, dying b

Updated on:December 22,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on: December 19,2023

Banking on breakthroughs for children and young people

byPhil Prime| Interview27 September 2022A partnership between Cancer Research UK and Blood Cancer UK has resulted in the UK’s leading biomedical research resource dedicated to storing samp

Updated on:December 19,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on: December 20,2023

Larotrectinib in tumours with NTRK gene fusion: Data are not yet sufficient

byInstitute for Quality and Efficiency in Health CareCredit: Institute for Quality and Efficiency in Health CareIn the summer of 2019, larotrectinib was approved as the first drug in Europe to b

Updated on:December 20,2023